EBS Emergent BioSolutions Inc.

Emergent BioSolutions Board Members Dr. Sue Bailey and Dr. Kathryn C. Zoon Named Most Influential Corporate Directors

Emergent BioSolutions Board Members Dr. Sue Bailey and Dr. Kathryn C. Zoon Named Most Influential Corporate Directors

GAITHERSBURG, Md., Dec. 20, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that two members of its board of directors – Dr. Sue Bailey and Dr. Kathryn C. Zoon – have been recognized as WomenInc. magazine's 2019 Most Influential Corporate Directors. 

“Sue and Kathy are trailblazers in their fields and continue to positively impact public health through their service on Emergent’s Board and their personal endeavors,” said Fuad El-Hibri, executive chairman of the board of directors of Emergent BioSolutions. “The strength of our board lies in the exemplar backgrounds and diverse perspectives each of our members bring and we are fortunate to have Sue and Kathy as engaged and passionate contributors.”

“On behalf of the Emergent family, I would like to express our sincere congratulations to Sue and Kathy for this well-deserved and prestigious recognition,” said Robert G. Kramer Sr., president and CEO of Emergent BioSolutions. “Their expert guidance, leadership, thoughtful stewardship, and personal mission to make the world a safer and healthier place help propel the company towards achieving our mission – to protect and enhance life. We are so proud of this accolade to add to their many achievements.” 

Dr. Bailey has served as a director since June 2007. She is an independent director and a member of the Compensation Committee, Nominating and Corporate Governance Committee, and Scientific Review Committee. Dr. Bailey served as a news analyst for NBC Universal, a media and entertainment company, from November 2001 to August 2006. Previously, Dr. Bailey served as Administrator, National Highway Traffic Safety Administration, as Assistant Secretary of Defense (Health Affairs) and as Deputy Assistant Secretary of Defense (Clinical Services). Dr. Bailey is a former faculty member at Georgetown Medical School and U.S. Navy officer, having achieved the rank of Lt. Commander, U.S. Navy Reserve.

Dr. Zoon has served as a director since October 2016. She is an independent director and a member of the Nominating and Corporate Governance Committee, Scientific Review Committee, and Strategic Operations Committee. Dr. Zoon is currently a Scientist Emeritus with the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH). Previously at NIAID/NIH she was the Chief of the Cytokine Biology Section, Director of the Division of Intramural Research, and Deputy Director for Planning and Development at the DIR. Dr. Zoon has also served as the Principal Deputy Director of the Center for Cancer Research at the National Cancer Institute, and as the Director of the Center for Biologics Evaluation and Research at the Food and Drug Administration. She has been a member of the National Academy of Medicine since 2002.

WomenInc. magazine is a cultural catalyst for professional women—a media platform that showcases and drives positive dialogue on and about women. This issue also features a discussion with Katy Strei, Emergent’s executive vice president, human resources and corporate communications and chief human resources officer, on “Shaping a Diverse and Inclusive Culture” and how Emergent has opened the aperture in thinking creatively and broadly about diversity and inclusion.

The full WomenInc. Influential Corporate Directors listing is available online and the WomenInc.'s winter issue is available nationwide at Barnes & Noble and newsstands.

About Emergent BioSolutions

Emergent BioSolutions Inc. is a global life sciences company seeking to protect and enhance life by focusing on providing specialty products for civilian and military populations that address accidental, deliberate, and naturally occurring public health threats. We aspire to be a Fortune 500 company recognized for protecting and enhancing life, driving innovation, and living our values. Additional information about the company may be found at Find us on LinkedIn and follow us on Twitter @emergentbiosolu and Instagram @life_at_emergent.

Investor Contact:

Robert G. Burrows

Vice President, Investor Relations

240-631-3280

Media Contact:

Lynn Kieffer

Vice President, Corporate Communications

240-631-3391

EN
20/12/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Emergent BioSolutions Inc.

 PRESS RELEASE

Emergent BioSolutions Receives U.S. FDA Approval of Supplemental New D...

Emergent BioSolutions Receives U.S. FDA Approval of Supplemental New Drug Application (sNDA) for NARCAN® Nasal Spray Multipacks Approval will broaden the NARCAN® Nasal Spray portfolio, and improve cost-effectiveness by increasing flexibility and distribution efficiency of this life-saving medication  GAITHERSBURG, Md., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Today, Emergent BioSolutions (NYSE: EBS) announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for new multipack configurations of over-the-counter (OTC) NARCAN® Nasal Spray. T...

 PRESS RELEASE

Emergent BioSolutions to Report Fourth Quarter and Full Year 2025 Fina...

Emergent BioSolutions to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 GAITHERSBURG, Md., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, February 26, 2026, at 5:00 pm eastern time to discuss the financial results for the fourth quarter and full year of 2025. Participants can access the conference call live via and also by visiting the page of Emergent’s website. To participate via telephone, please register in advance at this . Upon registration, all telephone participants will receive ...

Emergent Biosolutions Inc: 4 directors

Four Directors at Emergent Biosolutions Inc sold 89,428 shares at 10.920USD. The significance rating of the trade was 61/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ye...

 PRESS RELEASE

Emergent BioSolutions Receives U.S. FDA Approval on Supplemental New D...

Emergent BioSolutions Receives U.S. FDA Approval on Supplemental New Drug Application for NARCAN® Nasal Spray to be Packaged in a New Carrying Case, Making Life-Saving Naloxone More Accessible for Everyday Preparedness Since the U.S. prescription launch of NARCAN® Nasal Spray in 2016, the medicine has been trusted as a safe, effective way to reverse opioid overdoses, and today, new solutions like the NARCAN® carrying case aims to make accessibility paramount - ‘Trusted Then. Trusted Now’ GAITHERSBURG, Md., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Today, Emergent BioSolutions announced that the ...

 PRESS RELEASE

Emergent BioSolutions Announces $100 Million Paydown of Term Loan Prin...

Emergent BioSolutions Announces $100 Million Paydown of Term Loan Principal, a Significant Step Achieved Toward its Multi-year Transformation GAITHERSBURG, Md., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Today Emergent BioSolutions, Inc. (NYSE: EBS) announced it made a voluntary prepayment of $100 million under its outstanding term loan facility in late December 2025 using cash on hand. “This significant milestone reflects strong progress in improving our overall financial/cash position, enhancing our financial flexibility and positioning Emergent for long-term stability and growth,” stated Joe P...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch